Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database

Michele Fusaroli1, Valentina Isgrò2, Paola Maria Cutroneo3, Carmen Ferrajolo4, Valentina Cirillo5, Francesca Del Bufalo5, Emanuel Raschi1, Elisabetta Poluzzi1, Gianluca Trifirò2

Abstract

Introduction As chimeric antigen receptor T-cell therapies are becoming increasingly available in the armamentarium of the hematologist, there is an emerging need to monitor post-marketing safety.

Objective We aimed to better characterize their safety profile by focusing on cytokine release syndrome and identifying emerging signals.

Methods We queried the US Food and Drug Administration Adverse Event Reporting System (October 2017–September 2020) to analyze suspected adverse drug reactions to tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel). Disproportionality analyses (reporting odds ratio) were performed by comparing chimeric antigen receptor T-cell therapies with (a) all other drugs (reference group 1) and (b) other onco-hematological drugs with a similar indication, irrespective of age (reference group 2), or (c) restricted to adults (reference group 3). Notoriety was assessed through package inserts and risk management plans. Adverse drug reaction time to onset and cytokine release syndrome features were investigated.

Results Overall, 3225 reports (1793 axi-cel; 1433 tisa-cel) were identified. The reported toxicities were mainly: cytokine release syndrome (52.2%), febrile disorders (27.7%), and neurotoxicity (27.2%). Cytokine release syndrome and neurotoxicity were often co-reported and 75% of the events occurred in the first 10 days. Disproportionalities confirmed known adverse drug reactions and showed unexpected associations: for example, axi-cel with cardiomyopathies (reporting odds ratio = 2.3; 95% confidence interval 1.2–4.4) and gastrointestinal perforations (2.9; 1.2–7.3), tisa-cel with hepatotoxicity (2.5; 1.1–5.7) and pupil disorders (15.3; 6–39.1).

Conclusions Our study confirms the well-known adverse drug reactions and detects potentially emerging safety issues specific for each chimeric antigen receptor T-cell therapy, also providing insights into a stronger role for tisa-cel in inducing some immunodeficiency-related events (e.g., hypogammaglobulinemia, infections) and coagulopathies, and for axi-cel in neurotoxicity.

1 Introduction

Chimeric antigen receptor T (CAR-T) cells represent an innovative treatment in the hematology/oncology field. They are represented by autologous T cells, obtained through leukapheresis, engineered to express a chimeric receptor directed towards the selected tumor antigen, mostly CD-19.

1 Department of Medical and Surgical Sciences, Pharmacology Unit, University of Bologna, via Irnerio 48, Bologna, Italy
2 Department of Diagnostics and Public Health, University of Verona, Verona, Italy
3 Sicilian Regional Pharmacovigilance Centre, University Hospital of Messina, Messina, Italy
4 Regional Centre of Pharmacovigilance and Pharmacoepidemiology, Naples, Italy
5 Department of Pediatric Hematology/Oncology, Cellular and Gene Therapy, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy

Elisabetta Poluzzi and Gianluca Trifirò equal contribution as senior authors.

Elisabetta Poluzzi
elisabetta.poluzzi@unibo.it

© The Author(s) 2022

Accepted: 29 May 2022 / Published online: 12 July 2022
Chimeric antigen receptor T cells are innovative therapies for hematologic malignancies, for which a strict post-marketing monitoring has been recommended.

Our disproportionality analyses identified new potential signals, as cardiomyopathies and gastrointestinal perforations for axi-cel, hepatotoxicity and pupil disorders for tisa-cel.

Our findings provide insights into different safety profiles for the chimeric antigen receptor T-cell therapies investigated, and into a unified neurotoxicity-cytokine release syndrome.

Upon recognition of the target, the construct induces T-cell proliferation and activation against CD19+ B cells and B-cell precursors, both normal and malignant [1, 2]. Two second-generation CAR-T products, tisagenlecleucel (tisa-cel®) and axicabtagene ciloleucel (axi-cel®), were approved by the US Food and Drug Administration [3, 4] and the European Medicines Agency [5] for the treatment of relapsed or refractory (r/r) large B-cell lymphomas, such as diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Tisa-cel was also approved for the treatment of patients up to 25 years of age with r/r B-cell acute lymphoblastic leukemia (ALL) [6].

Although pivotal randomized controlled trials have shown extremely positive results in terms of efficacy for the two CAR-T cells, potentially life-threatening or even fatal toxicities have also been reported [7–9]. In particular, cytokine release syndrome (CRS) and neurotoxicity are two major complications that can lead to significant morbidity and mortality [10]. Cytokine release syndrome is a systemic inflammatory reaction associated with the release of cytokines, such as interleukin-6, interferon-γ, and tumor necrosis factor, occurring mainly in the first days after infusion. The broad spectrum of CRS-related signs includes fever, hypotension, hypoxia, depressed cardiac function, and organ dysfunction [11]. In pivotal trials, grade ≥ 3 CRS occurred in 22% of patients treated with tisa-cel and 11% of patients treated with axi-cel, with a median time to onset (TTO) of 3 days. Other adverse events reported with an incidence > 20% were hypogammaglobulinemia, infections, decreased appetite, headache, delirium, encephalopathy, bleeding episodes, nausea, diarrhea, vomiting, edema, fatigue, and acute kidney injury [7, 9].

Based on the pre-marketing assessment of their safety profile, in 2017, CAR-T cells were approved by the US Food and Drug Administration (FDA) with a Risk Evaluation and Mitigation Strategy, a program required for medications associated with serious safety concerns, as a risk minimization measure ensuring that benefits outweigh risks. In Europe, an accelerated assessment application through the Priority Medicines (PRIME) scheme for orphan diseases has been granted for CAR-T cells and additional monitoring and post-authorization safety studies have been required by the European Medicines Agency [12] after marketing authorization. Increasing post-marketing data have been recorded for CAR-T-cell safety profile monitoring in a real-world setting, where a significantly larger and heterogeneous population of patients has been treated [13–16].

In view of the several new CAR-T products recently approved by the FDA on the market (e.g., brexucabtagene autoleucel for mantle cell lymphoma in July 2020, lisocabtagepane maraleucel for DLBCL in February 2021, and idecabtagene vicleucel for multiple myeloma in March 2021), CAR-T cells are anticipated to be used in an increasing number of patients. This study aims to investigate the post-marketing safety profile of the well-established tisa-cel and axi-cel, analyzing spontaneous suspected adverse drug reaction (ADR) reports collected into the FDA Adverse Event Reporting System (FAERS) database, with the final goal to better characterize already known CAR-T-cell-related ADRs (primarily CRS) and to identify emerging safety reports of potential clinical relevance.

2 Methods

2.1 Data Source

The FAERS is a spontaneous reporting system collecting worldwide reports of suspected ADRs, submitted by heterogeneous reporters, with a range from healthcare professionals to patients and their families, lawyers, and manufacturers [17]. The FAERS data are available to the public in different ways: (a) a user-friendly public dashboard (available at the link: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard), containing many duplicates and limited information and (b) raw quarterly data downloadable as ASCII or XML files (available at the link: https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html), which need to be pre-processed but allow for more reliable analyses. Suspected ADRs are coded using preferred terms (PTs) from the Medical Dictionary for Regulatory Activities (MedDRA®), which has a hierarchical structure allowing the grouping of PTs at higher levels (i.e., High-Level Terms [HLTs]; High-Level Group Terms; System Organ Class).
ASCII files from the inception up to September 2020 were downloaded, merged, and active substances were translated to an implementation of the World Health Organization drug dictionary (accessed in March 2020) [18]. Data have been pre-processed to keep only the last update of each report and to remove duplicates, i.e., reports with the same information in all the following fields: sex, age, weight, country, date of the ADR, list of drugs (i.e., either suspect or concomitant), and list of ADRs.

### 2.2 Exposure of Interest

Reports of suspected ADRs related to tisa-cel and axi-cel from the post-marketing setting were retrieved in the period October 2017 to September 2020. In order to exclude all CAR-T-cell reports associated with pre-marketing experimental studies, we selected only reports related to approved indications for use and with entry dates following the first approval date (Table 1). As the main comparator (reference group 1, RG1), the reports of all other drugs collected in the same study period have been considered. In order to adjust for confounding by indication, only reports related to onco-hematological drugs, with an approved indication of use for ALL or DLBCL, have been considered as a second comparator (reference group 2, RG2). To correct also for age, RG2 reports restricted to adults (aged ≥ 18 years) have been considered as an additional reference group (RG3).

### 2.3 Data Analysis

Descriptive analyses have been carried out to explore and compare the characteristics of CAR-T-cell reports (e.g., age and sex of patients, temporal trends in reporting, reporter types) versus RG1, RG2, and RG3, and to describe the distribution of adverse events by MedDRA® HLTs. Continuous variables were summarized as median with interquartile ranges (IQRs) and categorical variables as percentages.

The reporting odds ratio (ROR) was used as a measure of ADR reporting disproportionality for signal detection (at the HLT level), with a statistical threshold that was defined as the lower limit of 95% confidence interval >1 in presence of three or more reports [19]. Disproportionality analyses on the FAERS database have already been applied with success to the oncological field, particularly to immunotherapy [20]. To reduce the risk of detecting false associations, we also calculated the information component (IC). The IC is a Bayesian disproportionality that applies shrinkage and converts to the base 2 logarithm the ratio between observed and expected cases [21]. If IC025 is estimated less than 0, we cannot with high confidence exclude that the disproportionality may be due to random variation and small numbers. Two authors evaluated the notoriety of prioritized ADRs, retaining significance on the three RGs. We considered unexpected the disproportions with HLTs that did not include PTs already included in the specific CAR-T-cell package inserts (i.e., the US FDA summary of product characteristics). To account for the redundancy of MedDRA® terms (i.e., the same event may be recorded with different terms), we considered expected also terms linked to those included in package inserts. Finally, important potential risks as defined by the European risk management plans (RMPs) [i.e., “concerns for which an association with the CAR-T cell is possible based on available data, but this association has not been established yet and needs further evaluation”] were investigated in depth through a case-by-case assessment. These potential risks were tumor lysis syndrome (only for axi-cel), second primary neoplasia, autoimmune conditions, and graft versus host disease (GvHD). Data considered in the case-by-case assessment were those concerning the drug and the event, sex, age, outcome, and TTO.

To assess the TTO of suspected ADRs, we calculated the number of days that elapsed from the beginning of the CAR-T-cell cycle up to the onset of suspected ADRs at their System Organ Class level and for HLTs and PTs of interest. Time to onset was summarized as the median and IQR.

To investigate the co-occurrence of CRS and other ADRs, a network analysis with HLTs as nodes and relevant relationships as links was performed, by employing validated methods for psychopathological symptoms in clinical settings (Ising estimation) [22], already applied to pharmacovigilance [23]. Links’ weights were estimated as partial correlations between each pair of HLTs conditioning on all

### Table 1 Indication of use of CAR-T cells marketed till the end of the observation period

| CAR-T                | Indication of use                                                                 | Date of FDA approval |
|----------------------|----------------------------------------------------------------------------------|----------------------|
| Tisagenlecleucel     | Patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma not otherwise specified, high grade B-cell lymphoma, and diffuse large B-cell lymphoma arising from follicular lymphoma | 30 August, 2017      |
| Axicabtagene ciloleucel | Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy | 18 October, 2017     |

*CAR-T* chimeric antigen receptor T, *FDA* US Food and Drug Administration

△ Adis
other HLTs. A LASSO (least absolute shrinkage and selection operator) procedure was performed to filter out spurious associations. Data management and analysis were performed using the packages tidyverse, datatable, ggradar, qgraph, visNetwork, and IsingFit of the “R” software (version 4.02).

### 3 Results

#### 3.1 Descriptive Analysis

Among 3,253,919 overall reports collected in the FAERS during the period October 2017–September 2020, a total of 3225 CAR-T-cell reports from the post-marketing setting were identified: 1793 (55.6%) for axi-cel and 1433 (44.4%) for tisa-cel (in one case, both CAR-T cells were reported). Additionally, 3,250,642 reports other than CAR-T have been selected as RG1, including 142,083 reports of drugs for hematology/oncology indications (RG2) and, of these, 74,170 (52.2%) were restricted to adults (RG3) (Fig. 1). Of the 1441 axi-cel reports with a specified indication of use, 1433 (99.4%) referred to non-Hodgkin B-cell lymphoma, eight to lymphocytic leukemia. Of the 1276 tisa-cel reports with a specified indication for use, 744 (58.3%) referred to lymphocytic leukemia, and 532 (41.7%) to non-Hodgkin B-cell lymphoma.

As compared with RG1, a higher percentage of CAR-T-cell reports regarded male patients (60.5% for axi-cel; 59.6% for tisa-cel) versus 38.7%. Among tisa-cel reports, the median age was 21 (IQR = 12–60) years, with 42.4% of reports in patients aged younger than 18 years, whereas in axi-cel it was 61 (52-68).

Chimeric antigen receptor T-cell-related ADRs were reported by medical doctors (N = 604; 35.6% for axi-cel; N = 769; 54.2% for tisa-cel) and other healthcare practitioners (N = 298; 17.6% for axi-cel; N = 203; 14.3% for tisa-cel) more often than RG1 (22.6% and 6.5%, respectively) (Table 2). A higher proportion of serious ADRs was observed for CAR-T cells (94.6%) compared with RG1 (56.2%), and RG2 (76.9%), with death accounting for 16.6% of axi-cel-related reports and 27.0% of tisa-cel-related reports (vs 8.2 in RG1 and 10.5 in RG2) (Table 2). Immune and associated conditions not elsewhere classified (NEC) [46.7%, e.g., CRS, hemophagocytic lymphohistiocytosis (HLH)], febrile disorders (35.3%), and alterations in white blood cell counts (30.8%, mostly a decrease) were the adverse events by HLTs more frequently reported for tisa-cel, while immune and associated conditions NEC (56.7%), nervous system disorders NEC (35.6%, i.e., neurotoxicity), and febrile disorders (21.7%) were the top three adverse events by HLTs reported for axi-cel. Noteworthy, neoplasm malignant site unspecified NEC-related events—more than 90% malignant neoplasm progression—were more reported...
### Table 2  Descriptive analyses of the main characteristics of the CAR-T reports vs reports of reference groups

|                          | Axi-cel  | Tisa-cel | RG1   | RG2   | RG3   |
|--------------------------|----------|----------|-------|-------|-------|
|                          | N (%)    | N (%)    | N (%) | N (%) | N (%) |
| **No. of reports**       | 1793     | 1433     | 3,250,642 | 142,083 | 74,170 |
| **Sex**                  |          |          |       |       |       |
| Female                   | 629 (39.5) | 517 (40.4) | 1,777,421 (61.3) | 73,244 (56.9) | 41,768 (56.9) |
| Male                     | 963 (60.5) | 763 (59.6) | 1,124,251 (38.7) | 55,561 (43.1) | 31,641 (43.1) |
| Missing/other            | 201      | 153      | 348,970 | 13,278 | 761 |
| **Age group, years**     |          |          |       |       |       |
| < 18                     | 5 (0.4)  | 480 (42.4) | 134,880 (66.6) | 5807 (7.3) | – |
| 18–64                    | 899 (63.4) | 438 (38.7) | 1,149,796 (56.2) | 37,746 (47.2) | 37,746 (50.9) |
| ≥ 65                     | 513 (36.2) | 214 (18.9) | 762,302 (37.2) | 36,424 (45.5) | 36,424 (49.1) |
| Median [Q1–Q3]           | 61 [52–68] | 21 [12–60] | 59 [41–70] | 63 [50–72] | 64 [54–73] |
| **Missing**              | 376      | 301      | 1,203,664 | 62,106 | – |
| **Country**              |          |          |       |       |       |
| North America            | 1469 (82.0) | 1176 (84.5) | 2,422,692 (77.2) | 99,246 (72.3) | 46,974 (65.8) |
| Europe                   | 310 (17.3) | 170 (12.2) | 496,833 (15.8) | 28,104 (20.5) | 17,484 (24.5) |
| Asia                     | 12 (0.7)  | 46 (3.3)  | 219,408 (7.0) | 9933 (7.2) | 6950 (9.7) |
| Missing/other            | 2        | 41       | 111,709 | 4800   | 2726 |
| **Reporter type**        |          |          |       |       |       |
| Consumer                 | 109 (6.4) | 229 (16.1) | 1,483,749 (46.9) | 28,796 (20.4) | 14,078 (19.2) |
| Medical doctor           | 604 (35.6) | 769 (54.2) | 713,944 (22.6) | 40,133 (28.4) | 22,621 (30.6) |
| Pharmacist               | 114 (6.7)  | 15 (1.1)  | 272,985 (8.6) | 32,475 (23.0) | 13,726 (18.6) |
| Healthcare practitioner  | 298 (17.6) | 203 (14.3) | 205,650 (6.5) | 15,532 (11.0) | 9533 (12.9) |
| Specified as other       | 572 (33.7) | 202 (14.3) | 449,577 (14.2) | 24,368 (17.2) | 13,828 (18.7) |
| Missing                  | 96       | 15       | 124,737 | 779    | 384 |
| **Reporting year**       |          |          |       |       |       |
| 2017 (Oct–Dec)           | 3 (0.1)  | 23 (1.6)  | 232,984 (7.2) | 9224 (6.5) | 4987 (6.7) |
| 2018                     | 475 (26.5) | 269 (18.8) | 1,072,523 (33.0) | 44,388 (31.2) | 23,929 (32.3) |
| 2019                     | 731 (40.8) | 706 (49.3) | 1,125,114 (34.6) | 47,480 (33.4) | 24,688 (33.3) |
| 2020 (Jan–Sep)           | 584 (32.6) | 435 (30.3) | 820,021 (25.2) | 40,991 (28.9) | 20,566 (27.7) |
| Specified as serious     | 1696 (94.6) | 1345 (93.9) | 1,826,595 (56.2) | 109,288 (76.9) | 64,213 (86.6) |
| **Seriousness**          |          |          |       |       |       |
| Death                    | 298 (16.6) | 387 (27.0) | 266,475 (8.2) | 14,976 (10.5) | 9458 (12.8) |
| Life threatening         | 83 (4.6)  | 100 (7.0)  | 73,516 (2.3) | 4184 (2.9) | 2767 (3.7) |
| Disability               | 24 (1.3)  | 4 (0.3)   | 42,501 (1.3) | 1964 (1.4) | 1319 (1.8) |
| Required intervention    | 1 (0.1)   | 0 (0)     | 2597 (0.1) | 4 (<0.1) | 3 (<0.1) |
| Hospitalization          | 592 (33.0) | 293 (20.4) | 613,184 (18.9) | 37,346 (26.3) | 23,846 (32.2) |
| Congenital abnormality   | 0 (0)     | 1 (0.1)   | 6298 (0.2) | 82 (0.1) | 18 (<0.1) |
| Other serious            | 698 (38.9) | 560 (39.1) | 822,024 (25.3) | 50,732 (35.7) | 26,802 (36.1) |
| **Drugs per report median [Q1–Q3]** | 1 [1–6] | 3 [1–4] | 2 [1–4] | 7 [4–12] | 8 [4–13] |
| **Suspected drugs per report median [Q1–Q3]** | 1 [1–1] | 1 [1–1] | 1 [1–2] | 2 [1–3] | 2 [1–4] |
| **Events per report median [Q1–Q3]** | 3 [1–5] | 5 [2–9] | 2 [1–4] | 2 [1–5] | 3 [1–6] |

To account for the incompleteness characteristic of spontaneous reporting databases, percentages were calculated for each variable, over reports with a specified value (valid percentage).

*Axici-cel* axicabtagene ciloleucel, *CAR-T* chimeric antigen receptor T, *RG1* reference group 1 (all reports other than the ones related CAR-T cells), *RG2* reference group 2 (reports related to onco-hematological drugs with indication for use specified for acute lymphoblastic leukemia or diffuse large B-cell lymphoma), *RG3* reference group 3 (onco-hematological drug reports with indication for use specified for acute lymphoblastic leukemia or diffuse large B-cell lymphoma in adult population specifically), *Tisa-cel* tisagenlecleucel

△ Adis
for tisa-cel than for axi-cel (22.7% vs 0.9%, respectively) [see Fig. 2 and Table S1 of the Electronic Supplementary Material (ESM)].

### 3.2 Disproportionality Analysis

Many disproportionality signals correspond to side effects already reported in package inserts, such as immune-related conditions (i.e., CRS and HLH), immunodeficiency, and neurotoxicity (see Table 3 and Table S2–5 of the ESM). New potential signals were also identified. For axi-cel, the main disproportions in decreasing frequency of report count were bladder and urethral symptoms (ROR = 2.1, 1.5–3.1; IC = 1, 0.4–1.4; i.e., urinary incontinence), cardiomyopathies (ROR = 2.3, 1.2–4.4; IC = 1, 0–1.8) and gastrointestinal ulcers and perforation, site unspecified (ROR = 2.9, 1.2–7.3; IC = 1.2, −0.3 to 2.2). For tisa-cel, new signals were the following: neoplasms malignant site unspecified NEC (ROR = 18.7, 15.6–22.3; IC = 3.5, 3.3–3.7; i.e., malignant neoplasm progression, second primary malignancies), metabolic acidosis (ROR = 8.2, 4.5–14.9; IC = 2.5, 1.6–3.2), paralysus and paresis (ROR = 3.6, 1.9–6.6; IC = 1.6, 0.6–2.3), hepatic failure and associated disorders (ROR = 2.5, 1.1–5.7; IC = 1.1, −0.3 to 2), and pupil disorders (ROR = 15.3, 6–39.1; IC = 2.6, 1.1–3.6).

### 3.3 Risk Management Plan-Driven Case-by-Case Assessment

Reports of adverse events listed in RMPs were also explored (see Tables S6–9 of the ESM):

- Fifty cases of second primary non-hematological neoplasia were reported with axi-cel (17 reports, 0.95%) and tisa-cel (33 reports, 2.30%) versus 3.62% in RG2 and 4.37% in RG3. In 32 of these, a specific cancer was recorded (most frequently involving skin [seven cases], genitourinary tract [six cases], lung [five cases], and the liver and pancreas [three cases]);
- Twenty-nine cases of autoimmune conditions (mostly affecting nervous tissue [Guillain–Barre syndrome, myelitis, encephalitis] in patients aged more than 40 years, and only one case in a young patient [Crohn’s disease in a 13-year-old boy]) were reported with axi-cel (11 reports, 0.61%) and tisa-cel (18 reports, 1.26%);
- Fourteen reports of GvHD (all with tisa-cel, 0.98%, in patients aged younger than 25 years), including one involving the lung, one the skin, one the gastrointestinal tract, and one involving the skin, liver, and gastrointestinal tract;
- Five reports of tumor lysis syndrome with axi-cel (0.28%; two specified latencies of 8 and 2 days).
| Disproportionalities in RG3 | Axi-cel | Tisa-cel | Notoriety from package insert | Important potential risks from RMP |
|-----------------------------|---------|---------|-------------------------------|---------------------------------|
|                             | N       | ROR (95% CI) | N | ROR (95% CI) | PIs$^a$ (N) | Axi-cel | PTs$^a$ (N) | Tisa-cel |
|                             |         |          |     |              | Neutropenia (64) | Yes | Neutropenia (38) | Yes |
| Blood and lymphatic system disorders |         |          |     |              | Febrile neutropenia (56) | Yes | Febrile neutropenia (28) | Yes |
| Neutropenias                 | 119     | 1.7 (1.4–2) | 65 | 2 (1.5–2.6) | Yes | Neutropenia (38) | Yes |
| Marrow depression and hypoplastic anemias |         |          |     |              | Pancytopenia (62) | Yes | Pancytopenia (20) | Yes |
| Blood and lymphatic system disorders |         |          |     |              | Cytopenia (31) | Yes | Cytopenia (69) | Yes |
| Coagulopathies               | 17      | 2.6 (1.6–4.3) | 27 | 9.9 (6.6–14.8) | Linked | Neutropenia (64) | Yes |
| Coagulation factor deficiencies | –       | –       | 5  | 36.5 (13.3–99.9) | Yes | Disseminated intravascular coagulation (12) | Yes |
| Thrombocytopenias            | –       | –       | 39 | 2.9 (2.1–4.1) | Yes | Hypofibrinogenæmia (5) | No |
| Lymphatic system disorders NEC | –       | –       | 10 | 2.4 (1.2–4.5) | Yes | Thrombocytopenia (38) | Yes |
| Spleen disorders             | –       | –       | 6  | 4 (1.7–9.1) | No | Heparin-induced thrombocytopenia (1) | No |
| Cardiac disorders            |         |          |     |              | Lymphadenopathy (6) | No | Lymphadenopathy (6) | No |
| Rate and rhythm disorders NEC | 94      | 6.4 (5.1–8) | 28 | 3.7 (2.5–5.5) | Yes | Cardiac arrest (7) | No |
| Supraventricular arrhythmias | 53      | 2.6 (1.9–3.4) | – | – | Yes | Cardiac arrest (7) | No |
| Ventricular arrhythmias and cardiac arrest | 38      | 3.9 (2.7–5.4) | 12 | 2.5 (1.4–4.5) | Yes | Cardiac arrest (7) | No |
| Heart failures NEC           | 31      | 1.6 (1.1–2.3) | – | – | Yes | Cardiac failure (4) | No |
| Cardiomyopathies             | 10      | 2.3 (1.2–4.4) | – | – | Yes | Cardiac failure (4) | No |
| Pericardial disorders NEC    | –       | –       | 5# | 2.7 (1.1–6.7) | Pericardial effusion (5) | No |
| HLTs                                      | Axi-cel | Tisa-cel | Axi-cel | Tisa-cel | Axi-cel | Tisa-cel |
|------------------------------------------|---------|----------|---------|----------|---------|----------|
| Notoriety from package insert            | PTs² (N)|          | PTs² (N)|          |         |          |
| Important potential risks from RMP      |         |          |         |          |         |          |
| **Congenital disorders**                 |         |          |         |          |         |          |
| Congenital disorder NEC                  | –       | –        | 4#      | 5.9 (2.1–16.1) | Aplasia (4) | No |
| **Eye disorders**                        |         |          |         |          |         |          |
| Pupil disorders                          | –       | –        | 5       | 15.3 (6–39.1) | Pupils unequal (2) | Linked |
| **Gastrointestinal disorders**           |         |          |         |          |         |          |
| Gastrointestinal ulcers and perforation, site unspecified | 5# | 2.9 (1.2–7.3) | – | – | Gastrointestinal perforation (4) | No |
| Gastrointestinal vascular occlusion and infarction | 4# | 4.9 (1.7–13.7) | – | – | Diverticular perforation (1) | No |
| Peritoneal and retroperitoneal hemorrhages | 3# | 6.6 (1.9–22) | – | – | Intestinal ischemia (4) | No |
| Abdominal findings abnormal              | –       | –        | 3#      | 6.3 (1.9–20.3) | Abdominal mass (3) | No |
| Hepatobiliary disorders                  |         |          |         |          |         |          |
| Hepatic failure and associated disorders  | –       | –        | 16#     | 2.5 (1.1–5.7) | Hepatic failure (16) | No |
| Cholestasis and jaundice                 | –       | –        | 8       | 2.8 (1.3–5.7) | Hyperbilirubinemia (4) | No |
| Cholestasis and jaundice                 | –       | –        | 8       | 2.8 (1.3–5.7) | Hyperbilirubinemia (4) | No |
| Immunodeficiency disorders NEC            | 850     | 92.7 (82.1–104.6) | 333     | 44.8 (38.2–52.7) | Cytokine release syndrome (330) | Yes |
| Immunodeficiency disorders NEC            | 24      | 2.2 (1.4–3.4) | 120     | 35.7 (28.7–44.4) | Hemophagocytic lymphohistiocytosis (14) | Yes |
| Immunodeficiency disorders NEC            |         |          |         |          |         | Both CAR-T cells GvHD | Yes |
| Immunodeficiency disorders NEC            |         |          |         |          |         | Both CAR-T cells GvHD | Yes |
| Immunodeficiency disorders NEC            |         |          |         |          |         | Both CAR-T cells GvHD | Yes |
| Table 3 | (continued) |  |
|------|-------------|------|
| Disproportionalities in RG3 | | |
| HLTs | Axi-cel | Tisa-cel | Notoriety from package insert | Axi-cel | Tisa-cel | Important potential risks from RMP |
|------|----------|----------|-----------------------------|---------|----------|---------------------------------|
| | N | ROR (95% CI) | N | ROR (95% CI) | | |
| Infections and infestations | | | | | | |
| Sepsis, bacteremia, viremia, and fungemia NEC | | | | | | |
| Clostridia infections | 78 | 1.6 (1.3–2.1) | 34 | 1.5 (1.1–2.2) | Sepsis (36) | Linked Sepsis (17) | Linked |
| | | | | | Septic shock (22) | | Linked Bacteremia (8) | Linked |
| | 22 | 2.6 (1.7–4) | 10 | 2.5 (1.3–4.7) | Clostridium difficile infection (11) | Linked Clostridium difficile infection (8) | Linked |
| | | | | | Clostridium difficile colitis (9) | Linked Clostridium difficile colitis (2) | Linked |
| Staphylococcal infections | 19 | 2.1 (1.3–3.4) | 27 | 7.1 (4.8–10.6) | Staphylococcal infection (12) | Linked Staphylococcal infection (24) | Linked |
| | | | | | Staphylococcal bacteremia (4) | Linked Staphylococcal bacteremia (3) | Linked |
| Pseudomonal infections | 12 | 3.7 (2–6.7) | 7 | 4.6 (2.1–9.9) | Pseudomonas infection (5) | Linked Pseudomonas infection (6) | Linked |
| Polymavirus infections | 10# | 2.1 (1.1–4.1) | 7 | 3.3 (1.5–7) | Progressive multifocal leukoencephalopathy (7) | Linked Bk virus infection (7) | Linked |
| | | | | | Jc virus infection (4) | Linked | Linked |
| Enterococcal infections | 9 | 2.9 (1.5–5.7) | 16 | 12.2 (7.2–20.6) | Enterococcal infection (5) | Linked Enterococcal infection (15) | Linked |
| | | | | | Urinary tract infection enterococcal (2) | Linked Enterococcal sepsis (1) | Linked |
| Escherichia infections | – | – | 6# | 2.6 (1.1–6) | Escherichia infection (3) | Linked Escherichia urinary tract infection (2) | Linked |
| Klebsiella infections | – | – | 5 | 4.1 (1.6–10) | Klebsiella infection (4) | Linked Pneumonia Klebsiella (1) | Linked |
| Viral infections NEC | – | – | 17 | 2.6 (1.6–4.2) | Viral upper respiratory tract infection (7) | Linked Viral sinusitis (5) | Linked |
| Rhinoviral infections | – | – | 21 | 71.8 (41.5–124.1) | Rhinovirus infection (21) | Linked |
| Adenoviral infections | – | – | 5 | 12.4 (4.9–31.3) | Adenovirus infection (5) | Linked |
| Coronavirus infections | – | – | 6# | 2.8 (1.2–6.5) | Coronavirus infection (5) | Linked COVID-19 (1) | Linked |
| Respiratory syncytial viral infections | – | – | 5 | 7.6 (3–19) | Respiratory syncytial virus infection (11) | Linked |
Table 3 (continued)

| Disproportionals in RG3 | Notoriety from package insert | Important potential risks from RMPHLTs |
|-------------------------|-------------------------------|----------------------------------------|
| HLTs                    | Axi-cel                       | Tisa-cel                               |
|                         | $N$                           | ROR (95% CI)                           | $N$                           | ROR (95% CI) | PTs* (N) | Axi-cel | PTs* (N) | Tisa-cel | |
| Fungal infections NEC   | –                             | –                                      | 22                            | 3.8 (2.5–6) | Fungal infection (10) | Yes |
|                         | –                             | –                                      | 11                            | 2.5 (1.4–4.6) | Mucormycosis (5)      | Linked |
| Candida infections      | –                             | –                                      | 10                            | 4.9 (2.5–9.2) | Candida infection (11) | Linked |
| Aspergillus infections  | –                             | –                                      | 12                            | 8.2 (4.5–14.9) | Systemic candida (1)  | Linked |
|                        | –                             | –                                      | 8                             | 3 (1.5–6.2)   | Aspergillus infection (5) | Linked |
| Metabolism and nutrition disorders |                  |                                          |                                |                      | Tumor lysis syndrome (8) | Yes |
| Sodium imbalance        | 15                            | 2.7 (1.6–4.6)                          | –                             | –                                      | Tumor lysis syndrome (8) | Yes |
| Electrolyte imbalance NEC | –                             | 3 (1.5–6.2)                          | –                             | –                                      | Tumor lysis syndrome (8) | Yes |
| Metabolic acidoses      | –                             | 12                                      | 8                             | 3 (1.5–6.2)   | Lactic acidosis (9)     | No |
| (excluding diabetic acidoses) |                        |                                          |                                |                      | Metabolic acidosis (3)  | No |
| Mixed acid-base disorders | –                             | 6                                      | 12                            | 25 (10.3–60.7) | Acidosis (6)           | No |
| Neoplasms benign, malignant, and unspecified (including cysts and polyps) |               |                                          |                                |                      | Malignant neoplasm progression (170) | No |
| Neoplasms malignant site unspecified NEC | –                             | 186                                     | 18.7 (15.6–22.3) | Malignant neoplasm progression (170) | No |
| Nervous system disorders | 528                           | 76.3 (66.6–87.3)                       | 122                           | 17.4 (14.1–21.3) | Neurotoxicity (516)     | Yes |
| Nervous system disorder NEC |                        |                                          |                                |                      | Neurotoxicity (112)    | Yes |
| Encephalopathies toxic and metabolic | 147                           | 60.2 (47.5–76.3)                       | 25                            | 11.2 (7.4–17.1) | Immune effector cell-associated neurotoxicity syndrome (139) | Linked |
| Encephalopathies NEC    | 137                           | 23.4 (19–28.7)                        | 28                            | 7.4 (5–11)     | Toxic encephalopathy (5) | Linked |
| Cortical dysfunction NEC | 116                           | 31 (24.6–39.1)                        | 26                            | 10.2 (6.8–15.4) | Aphasia (103)           | Yes |
|                         |                               |                                          |                                |                      | Aphasia (22)           | No |

*PTs: Patient treatment summary*
Table 3 (continued)

| Disproportionals in RG3 | Axi-cel | Tisa-cel | Notoriety from package insert | Important potential risks from RMPHLTs |
|-------------------------|---------|---------|-----------------------------|----------------------------------------|
|                         | N       | ROR (95% CI) | N       | ROR (95% CI) | PTs² (N) | Axi-cel | PTs² (N) | Tisa-cel |                         |
| Disturbances in conscious-ness NEC | 93 | 2.5 (2–3.1) | 44 | 2.5 (1.8–3.5) | Somnolence (70) | Yes | Depressed level of consciousness (28) | Yes | Syncope (10) | Yes | Somnolence (15) | Yes | Depressed level of consciousness (10) | Yes |
| Tremor (excluding congenital) | 74 | 6.9 (5.3–8.8) | 26 | 4.8 (3.2–7.2) | Lethargy (10) | Yes | Tremor (72) | Linked | Intention tremor (2) | Linked | Tremor (26) | Yes | |
| Seizures and seizure disorders NEC | 43 | 3.9 (2.8–5.3) | 15 | 2.8 (1.6–4.7) | Seizure (29) | Yes | Seizure (10) | Yes | Status epilepticus (9) | Linked | Status epilepticus (5) | Yes | |
| Memory loss (excluding dementia) | 40 | 3.1 (2.2–4.3) | – | – | Memory impairment (34) | Yes | Amnesia (6) | Linked | |
| Speech and language abnormalities | 26 | 3.9 (2.6–5.8) | – | – | Dysarthria (12) | Linked | Speech disorder (11) | Yes | |
| Mental impairment (excluding dementia and memory loss) | 18 | 2.8 (1.7–4.6) | – | – | Cognitive disorder (11) | Yes | Disturbance in attention (6) | Yes | |
| Increased intracranial pressure disorders | 11 | 4.7 (2.5–8.8) | 8 | 7.4 (3.6–15.2) | Brain oedema (10) | Linked | Brain edema (6) | Linked | Intracranial pressure increased (1) | Linked | Intracranial pressure increased (2) | Linked | |
| Encephalitis NEC | 3# | 7.5 (2.2–25.4) | – | – | Noninfective encephalitis (3) | No | |
| Autonomic nervous system disorders | 3# | 9.3 (2.7–32) | – | – | Autonomic neuropathy (2) | No | Orthostatic intolerance (1) | No | Generalized tonic-clonic seizure (5) | Linked | |
| Generalized tonic-clonic seizures | – | – | 5 | 10.4 (4.1–26.1) | Cerebrovascular accident (4) | Linked | Cerebral infarction (3) | Linked | Embolic stroke (3) | Linked | |
| Central nervous system hemorrhages and cerebrovascular accidents | – | – | 17# | 1.6 (1–2.6) | Hemiparesis (9) | No | Paraparesis (7) | No | Noninfectious myelitis (2) | No | Myelitis transverse (2) | No | |
| Paralysis and paresis (excluding cranial nerve) | – | – | 11 | 3.6 (1.9–6.6) | |
| Myelitis (including infective) | – | – | 4 | 25.9 (8.7–76.7) | |
| Disproportionalities in RG3 | Axi-cel | Tisa-cel | Notoriety from package insert | Important potential risks from RMPHLS |
|-----------------------------|---------|---------|-----------------------------|-------------------------------------|
| **Acute polyneuropathies** | –       | –       | 3# 7.2 (2.2–23.4)           | Guillain–Barré syndrome (3)         |
| **Psychiatric disorders**   |         |         |                             |                                     |
| Confusion and disorientation | 136     | 9.2 (7.6–11.1) | 35 4.4 (3.1–6.2) | Confusional state (123) Yes | Confusional state (30) Yes |
| Mental disorders NEC        | 29      | 6.8 (4.6–10)  | 16 7.8 (4.6–13) | Disorientation (39) Yes | Disorientation (9) Linked |
| Deliria                     | 16      | 4.4 (2.6–7.4) | 11 6.5 (3.5–12.1) | Mental status changes (27) Yes | Mental status changes (15) Yes |
| Thinking disturbances       | 13      | 11 (6–20)   | – – – | Bradyphrenia (10) Linked |                                    |
| Communications disorders    | 6       | 24.5 (9.3–64.7) | – – | Tangentiality (2) Linked |                                    |
| Speech and language usage disturbances | 3# | 26.5 (6.6–106.2) | – – | Communication disorder (5) Linked |                                    |
| Hallucinations (excluding sleep related) | – | – | 10 5.6 (2.9–10.7) | Disorganised speech (3) Linked | Hallucination (9) No |
| Nephropathies and tubular disorders NEC | – | – | 5# 3.6 (1.4–8.9) | Incontinence (15) No | Nephropathy toxic (5) Linked |
| Renal vascular and ischaemic conditions | – | – | 3# 4.2 (1.3–13.3) | Urinary incontinence (6) No | Renal tubular Necrosis (3) Linked |
### Table 3 (continued)

| Disproportionalities in RG3                  | Notoriety from package insert | Important potential risks from RMP |
|----------------------------------------------|------------------------------|-----------------------------------|
| HLTs                                         | Axicel PTs^a (N)              | Axi-cel                           | Tisa-cel                        |
| N (95% CI)                                  | Axi-cel                       | Tisa-cel                          |
| Respiratory, thoracic, and mediastinal disorders |                              |                                   |
| Conditions associated with abnormal gas exchange | Hypoxia (64)         | Yes Hypoxia (57)                  |
| axicabtagene ciloleucel                       | 64 (6.9–11.9)                | 58 (14–24.9)                      |
| Pneumothorax and pleural effusions NEC       | Hypocapnia (1)               | No                                |
| axicabtagene ciloleucel                       | 33 (1.5–3.1)                 |                                    |
| Respiratory failures                          | Pleural effusion (31)        | Yes                               |
| (excluding neonatal)                          | axicabtagene ciloleucel       |                                    |
| Respiratory failure                           | Respiratory failure (15)      | Yes                               |
| axicabtagene ciloleucel                       | 27 (1.3–3)                   | 21 (2.2–5.4)                      |
| Acute respiratory failure                     | Respiratory failure (6)       | Yes                               |
| axicabtagene ciloleucel                       | 2 (1.3–3)                    | 6# (1.1–5.7)                      |
| Lower respiratory tract signs and symptoms    | Acute respiratory failure (6) | Yes                               |
| axicabtagene ciloleucel                       |                            |                                    |
| Vascular disorders                            | axicabtagene ciloleucel       |                                    |
|axicabtagene ciloleucel                        | 2.6 (1.4–4.7)                |                                    |
| Hypotension                                  | Hypotension (148)            | Yes                               |
| axicabtagene ciloleucel                       | 6.4 (5.3–7.6)                | 107 (9.8–12.2)                    |
| Orthostatic hypotension                       | Orthostatic hypotension (8)  | Yes                               |
| axicabtagene ciloleucel                       | 2 (1.3–3)                    | 8 (3.8–8.7)                      |
| Shock                                        | Shock (7)                    | Linked                            |
| axicabtagene ciloleucel                       | 12 (1.4–4.7)                 | 8 (3.8–8.7)                      |
| Shock haemorrhagic                            | Shock haemorrhagic (2)       | Linked                            |
| axicabtagene ciloleucel                       |                            |                                    |

_Axicel_ axicabtagene ciloleucel, CI confidence interval, COVID-19 coronavirus disease 2019, GvHD graft vs host disease, HLT High-Level Term, NEC not elsewhere classified, PTs preferred terms, RMPs risk management plans, ROR reporting odds ratios, SOC System Organ Class, Tisa-cel tisagenlecleucel
^aTwo PTs more frequent reported
Onco-hematological HLTs were not shown

Linked = event not reported in the package insert as a PT but linked to other listed events (e.g., shock and hypotension, sepsis and infection, disorientation and confusion, dysgraphia and other cortical dysfunctions such as dyscalculia). Other important potential risks reported in RMPs of tisa-cel were: new occurrence or exacerbation of an autoimmune disorder, hematological disorders (including aplastic anemia and bone marrow failure)
3.4 Time to Onset

Time-to-onset analysis at the System Organ Class level (see Fig. S1 of the ESM) was restricted to reports with specified TTO (the TTO was unspecified in 1527 cases, 47.3%). Overall, 75% of the events occurred within 10 days (median = 5, IQR = 2–10 days; missing = 1527/3225) from CAR-T-cell administration, with immune (3, 2–6; 765/1809), cardiovascular (3, 2–7; 124/379), and neurological (4, 2–7; 572/1526) adverse events in the first week, and infections (6, 2–21; 390/751), and neoplasia (9, 2–44; 460/709) occurring also over a longer period.

3.5 Cytokine Release Syndrome In-Depth Analysis

Immune and associated conditions NEC occurred in 1685 (52.2%) CAR-T reports, with the following specific PTs: CRS in 1657 of the reports, HLH in 59, GvHD in 14, cytokine storm in 13, and other immune system disorder in four. As compared to RG2 (to avoid excluding suspected ADRs reported in children), statistically significant disproportionate reporting was observed for HLH (ROR = 12.07, 8.13–17.93 for axi-cel; ROR = 10.77, 7.38–15.71 for tisacel) and GvHD (14 cases, always in tisacel; ROR = 2.48, 1.45–4.23). Even if 90% of CRS events occurred within the first 10 days, we also found reports of delayed CRS (> 12 days), frequently co-reported with cytopenia (14% vs 4%). Based on the network analysis, vascular hypotensive disorders, conditions associated with abnormal gas exchange, nervous system disorders NEC, and encephalopathies toxic and metabolic were commonly reported together with immune and associated conditions NEC, whereas leukopenias NEC were preferentially reported without immune and associated conditions (Fig. 3).

4 Discussion

Our study explored the post-marketing safety profile of tisacel and axi-cel through the analysis of the US FAERS database. In particular, we focused on new potential safety signals, on the comparison of the two CAR-T cells, on CRS features, and on events to be monitored according to RMPs.

4.1 Case Demographics

The demographics of the CAR-T-cell reports were in line with previous pharmacovigilance studies [16, 24, 25]. More reports from male patients were expected (channeling bias), as both DLBCL and ALL show a higher prevalence in male patients, as reported by the US cancer scientific authority [26, 27]. Furthermore, differences in age among the two CAR-T-cell reports are explained by the indication for ALL in pediatric patients exclusive for tisacel [6].

We also found a higher frequency of serious suspected ADRs for CAR-T cells, as compared with all other drugs in FAERS as well as versus other drugs approved for the treatment of ALL and/or DLBCL. This finding is partly explained by the fact that CAR-T cells are administered only in r/r ALL and DLBCL, and a role of the Risk Evaluation and Mitigation Strategy program recommendations to report any serious suspected ADR cannot be excluded. In particular, we observed a slightly higher proportion of fatalities as compared with a previous study carried out in FAERS (21.2% vs 15.3%) [28]. As we included also reports outside the USA, which are collected only for serious and unexpected ADRs, this finding could be a result of the different reports evaluated.

Overall, the first 10 days following CAR-T-cell administration is the time window at the highest risk for developing serious ADRs. In line with a previous study performed in Vigibase [25], CRS and neurologic adverse events were reported to occur within the first week after CAR-T-cell administration.

4.2 New Potential Safety Signals

Our study confirmed well-known safety issues (e.g., CRS, cytopenia, neurotoxicity, rate and rhythm disorders) that have been reported in pivotal clinical trials as well as observational studies [7–9, 14, 24, 25, 29], and their management has been extensively addressed in the recent American Society of Clinical Oncology guidelines for the management of
immune-related ADRs in patients treated with CAR-T-cell therapy [30]. However, we found also new potential signals concerning ADRs that have not been described in the package insert. While disproportionate reporting of splenic and lymphatic disorders (e.g., lymphadenopathy and splenomegaly) with tisa-cel are plausibly related to its use in ALL, and can be explained as confounding by indication, cholestasis/jaundice and hepatic failure, metabolic disorders, lower respiratory tract signs and symptoms, and hallucinations represent new potential safety signals.

Previous studies found transaminases increase during CAR-T-cell administration, usually together with CRS [11, 31–33], whereas we found 16 cases of hepatic failure with tisa-cel. The fact that CRS was concomitantly recorded in all but three of these reports suggests that liver injury was plausibly a manifestation of CRS-mediated organ dysfunction, and not a drug-induced direct hepatotoxicity.

We also found a potential association with pupil disorders (i.e., pupils unequal, pupil fixed, and mydriasis) that could lead to visual impairment as already reported in the package insert (7% of treated patients in clinical trials) and to a higher contribution of visual disorders by tisa-cel observed in a recently published FAERS analysis [34].

Axi-cel, instead, was found to be also associated with gastrointestinal infarctions, hemorrhages, ulcers, and perforations. Accordingly, in a clinical study on the long-term effects of CAR-T cells, around 2% of patients died because of duodenal ulcer and perforation [35]. Nonetheless, it should be noted that tumor lysis of gastrointestinal lymphomas in this type of patient (listed as an important potential risk according to the RMP of axi-cel) could be partly responsible for these findings.

Furthermore, axi-cel was found to be associated with cardiomyopathies, in accordance with previous observational studies [13, 36]. It is important to note that, as shown by the negative IC025, we cannot exclude that the significant RORs for tisa-cel and hepatic failure, and for axi-cel and gastrointestinal ulcers and perforation were due to random variation and small numbers.

4.3 Potential Differences in Tisagenlecleucel and Axicabtagene Ciloleucel Safety Profiles

Potential differences in tisa-cel and axi-cel safety profiles emerged from our findings. In particular:

1. a stronger role for tisa-cel compared with axi-cel in inducing immunodeficiency-related disorders (especially infections) was supported by:
   (a) the higher proportion of reports describing fever (35.3 vs 21.7%), white blood cell count decrease (30.8 vs 2.9%), and immunodeficiency disorders NEC (17.1 vs 2.0%);
   (b) the stronger disproportionality with immunodeficiency disorders NEC even when limiting the analysis to adults (in RG3 ROR = 35.7, 28.7–44.4 vs 2.2, 1.4–3.4; IC = 4.4, 4.1–4.6 vs 1, 0.4–1.5);
   (c) the exclusive association, in RG3, with many infections, particularly by opportunistic agents (e.g., Aspergillus, Candida, fungi, Klebsiella).

2. a stronger role for tisa-cel compared with axi-cel in inducing coagulopathies was supported by:
   (a) the stronger association with coagulopathies (in RG3 ROR = 9.9, 6.6–14.8 vs 2.6, 1.6–4.3; IC = 2.9, 2.3–3.4 vs 1.3, 0.4–1.8);
   (b) the exclusive association with thrombocytopenias and coagulation factor deficiencies, also potentially associated with the already discussed hepatic failure;
   (c) the exclusive association with cerebrovascular accidents (even if IC025 < 0) and plausibly related events (e.g., paresis).

3. a stronger role for axi-cel compared with tisa-cel in inducing neuropsychiatric ADRs, supported by:
   (a) the higher proportion of reports describing nervous system disorders NEC (35.6 vs 16.7%);
   (b) a stronger association with neuropsychiatric events (e.g., in RG3 nervous system disorders NEC ROR = 76.3, 66.6–87.3 vs 17.4, 14.1–21.3; IC = 4.6, 4.5–4.7 vs 3.6, 3.3–3.8);
   (c) the exclusive association with many neurological events (i.e., memory loss, speech and language disorders, mental impairment, autonomic nervous system disorders, encephalitis NEC, thinking disturbances, communications disorders);
   (d) the exclusive association with incontinence, which is plausibly a symptom of severe neurotoxicity.
   (e) the consistency with results from a previous study performed on the FAERS public dashboard, in December 2019 [14].

The only neuro-psychiatric HLTs significantly associated with tisa-cel but not with axi-cel were the already mentioned vascular events, autoimmune conditions (myelitis and Guillain–Barré syndrome), and hallucinations.
4.4 Risk Management Plan-Driven Case-by Case Assessment

We found 50 cases of CAR-T cells related to second primary non-T-cell/non-hematological neoplasia (mostly skin, genitourinary, and lung cancer). Patients with non-Hodgkin lymphoma have a known higher risk for developing secondary malignancies [37, 38], as supported also by the comparable reporting proportion of non-hematological malignancies in both RG2 and RG3; therefore, the role of the underlying clinical condition of these patients cannot be excluded. Accordingly, ten reports of second primary non-hematological neoplasia occurred less than 1 month after CAR-T administration, thus pointing towards no causal association. Nonetheless, second primary malignancies are listed in the RMPs as plausible adverse reactions to CAR-T. In fact, the treatment with CAR-T cells could unmask and speed up the progression of pre-existing neoplasms, considering that it targets exclusively CD19-positive cells, therefore being ineffective on other malignancies. Moreover, the immunosuppression associated with the CAR-T treatment could be another favoring factor to be taken into account.

Twenty-nine reports of autoimmune, mostly neurological, conditions have also been identified, with a preferential association with tisa-cel. The hypothesized relationship between CAR-T cells and immune-related ADRs requires further assessment.

Graft versus host disease is another potential risk listed in the CAR-T-cell RMPs. Chimeric antigen receptor T-cell administration may have a role in aggravating pre-existing GvHD in relapsed patients after prior allogeneic hematopoietic stem cell transplantation, even if results from clinical trials are heterogeneous [8, 33, 39]. In FAERS, we identified 14 GvHD reports that occurred after tisa-cel administration, involving multiple anatomical sites (i.e., skin, liver, gastrointestinal tract, lung).

4.5 Cytokine Release Syndrome Features

Immune and associated conditions NEC occurred in 52.2% of CAR-T-cell reports: mainly as CRS and other overlapping terms (e.g., cytokine storm [40]), but also as hemophagocytic lymphohistiocytosis (considered a particularly severe form of CRS). The profile of CRS emerging from our analysis is in line with the literature, occurring around day 3 from the injection, and manifesting together with abnormal gas exchange and hypotension. Our findings, furthermore, point to a unified CRS-neurotoxicity framework, for the following reasons:

(a) the frequent co-reporting of CRS, neurotoxicity, and encephalopathies;
(b) a common TTO, limited mostly to the first week;
(c) a high proportion of neurotoxicity co-reported with CRS (in 30% of CRS cases it occurred within 10 days following the CAR-T injection, and in 36% of CRS cases it occurred after 10 days).

Indeed, CAR-T-cell-induced neurotoxicity occurs almost exclusively in patients experiencing also CRS, of any grade [41]. However, few reports of neurotoxicity occurring after resolution of CRS, or without CRS, have been recorded, suggesting the co-existence also of an independent pathogenic mechanism [42]. Interestingly, we found that 8% of CRS reports occurred after at least 12 days after the infusion (delayed CRS [43]).

4.6 Limitations and Strengths

In consideration of the observational nature of our study on FAERS, well-known limitations of these studies are related to the analysis of spontaneous reporting systems, including data missingness (e.g., disease burden and cancer site) and a lack of information on the exposed population (i.e., total patients treated with CAR-T cells). Moreover, it must be taken into account that CAR-T cells have been approved for the treatment of advanced disease, after the failure of several previous lines of treatment. Therefore, we cannot exclude that disproportionate reporting of some adverse events could be determined also by the effects of the treatments administered before CAR-T as well as comorbidities and the underlying clinical status of these heavily pretreated patients. The large-scale design of our study, while accounting for age and indication confounders, did not allow us to correct for biases affecting individual suspect ADRs. These biases should be considered in studies focused on individual drug-event combinations.

Our work relies on and underlines the important strengths of pharmacosurveillance that make it complementary to pivotal trials: the access to a population usually neglected in pre-marketing studies, a large population with reports from all over the world and an extended focus to any type of event. Moreover, we designed and performed disproportionality analyses taking into account potential biases and carefully scrutinizing potential signals, in relation to the information reported in the package insert and RMPs. The analysis performed at the HLT level allows the grouping of some of the MedDRA® terms with overlapping meanings (with higher numbers and accuracy), but at the cost of sometimes grouping not overlapping terms (e.g., hypernatremia and hyponatremia). We also performed RMP-driven individual case assessments to search for potential risks not optimally retrieved using an HLT. Finally, we exploited the richness of pharmacosurveillance data to better characterize CAR-T-related ADRs, particularly considering TTO and co-reporting of events.
5 Conclusions

The present analysis provides an overview of spontaneous reports of suspected ADRs occurring in patients treated with CAR-T cells. Our results strengthen the evidence provided by clinical trials and previous observational studies. We also found unexpected signals that are worthy of further evaluation, including gastrointestinal perforations and cardiomyopathies for axi-cel and hepatic failure and pupil disorders for tisa-cel. The higher frequency of reporting of non-hematologic second primary neoplasia does not support theory-based RMP alerts, pointing instead to the role of the underlying disease; nonetheless, further studies are needed to elucidate a possible additional contribution by CAR-T-cell therapy. Finally, we provided insights into a stronger role for tisa-cel in inducing immunodeficiency-related events (i.e., hypogammaglobulinemia and susceptibility to infections) and coagulopathies, and for axi-cel in neurotoxicity, and into a unified CRS-neurotoxicity syndrome.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s40264-022-01194-z.

Acknowledgements MF, ER, and EP were supported by institutional research funds (Ricerca Fondamentale Orientata).

Funding Open access funding provided by Alma Mater Studiorum - Università di Bologna within the CRUI-CARE Agreement.

Declarations

Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of Interest/Competing Interests MF, VI, PC, CF, FD, VC, and EP declare that they have no conflicts of interest. ER reports a personal fee for consultancy from Novartis, outside the submitted work.

Ethics Approval Anonymized data were collected from a publicly available database and do not require ethics committee approval.

Consent to Participate Not applicable.

Consent for Publication Not applicable.

Availability of Data and Material The datasets generated and/or analyzed during the current study are available in the US FAERS repository.

Code Availability The R script developed for the analyses is available from the corresponding author upon reasonable request.

Authors’ Contributions MF, VI, PC, CF, ER, FD, VC, ER, EP, and GT conceived and executed the research project. MF designed and executed the statistical analysis. MF, VI, PC, CF, ER, EP, and GT reviewed and critiqued the statistical analysis. All the authors contributed to the interpretation of data. Regarding article preparation, the writing of the first draft was executed by MF and VI, and all the authors contributed to the review and critique. All the authors approved the final version.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

References

1. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90:720–4.
2. Hartmann J, Schüßler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017;9:1183–97.
3. US FDA. FDA approves tisagenlecleucel for adults with relapsed or refractory large B-cell lymphoma. 2019. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisagenlecleucel-adults-relapsed-or-refractory-large-b-cell-lymphoma. Accessed 26 Jun 2022.
4. US FDA. FDA approves axicabtagene ciloleucel for large B-cell lymphoma. 2019. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-axicabtagene-ciloleucel-large-b-cell-lymphoma. Accessed 26 Jun 2022.
5. European Medicines Agency. First two CAR-T cell medicines recommended for approval in the European Union. 2018. https://www.ema.europa.eu/en/news/first-two-car-t-cell-medicines-recommended-approval-european-union. Accessed 26 Jun 2022.
6. US FDA. FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome. 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisagenlecleucel-b-cell-all-and-tocilizumab-cytokine-release-syndrome. Accessed 26 Jun 2022.
7. Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20:31–42.
8. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–17.
9. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56.
10. Neelapu SS, Tummala S, Kebrizai P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy: assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47–62.
